Adicet’s mission is to deliver best-in-class gamma delta T cell therapies for patients fighting autoimmune diseases & cancer

Chen Schor is President and CEO of Adicet Bio, a leader in the field of gamma-delta CAR T cell therapies for the treatment of autoimmune diseases and cancer. With more than 25 years of global biopharmaceutical leadership experience, he has led several biotech companies across all stages, from formation, to early-stage discovery, to publicly traded multi-product companies with significant industry partnerships. 

Mr. Schor has led strategic transactions valued at over $8 billion with companies such as GSK, Amgen, Pfizer, Merck KGaA and equity financing totaling more than $500 million. He led the turnaround of Synta Pharmaceuticals and its reverse merger with Madrigal Pharmaceuticals (Nasdaq: MDGL), served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals and in leadership positions at several emerging private and public companies. Mr. Schor was a Partner at Yozma Venture Capital where he led the foundation and growth of multiple therapeutic companies from inception to significant commercial success and exit.

He is a board member with the Alliance for Cancer Gene Therapy, a non-for-profit organization committed to advancing new cancer cell and gene therapies, Chairman of the Board of Carbon Biosciences, a gene therapy company, and board member with Karyopharm Therapeutics, a commercial stage oncology company.

Mr. Schor holds a MBA, a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA).

Dr. Aftab joined Adicet Bio in April 2021 with nearly 20 years of rich experience in academia, biotech and pharmaceutical industries developing multiple therapeutic modalities including small molecules, biologics, antibody-drug conjugates and cell therapies through all stages drug development. He joined Adicet from Atara Biotherapeutics, Inc., a publicly traded immunotherapy company, where, as Vice President and Head of Preclinical Science and Translational Medicine, he contributed to the company’s initial transition to cell therapy and led the focus on developing Allo-CAR T cell capabilities. Previously, Dr. Aftab led multiple research programs at University of California, San Francisco focused on drug discovery and clinical translation in multiple myeloma, including early research supporting targeted approaches for CD38 and other impactful targets of interest for CAR-T therapies. Dr. Aftab received his Ph.D. from The Johns Hopkins University School of Medicine and holds a B.Sc. in Pharmacology and Drug Discovery, from The University of California, Santa Barbara.

Dr. Nancy Boman is Chief Regulatory Officer of Adicet Bio. With nearly 30 years of experience in the biotech and pharmaceutical industry most recently in the cell and gene therapy space, Dr. Boman has expertise in Regulatory strategy and operations, clinical development and CMC. She has led more than 15 drug marketing applications in various indications including in hematologic malignancies, such as non-Hodgkin’s lymphoma and in solid tumors. 

Before joining Adicet, Dr. Boman served as Chief Regulatory Officer at Encoded Therapeutics where she built and oversaw all aspects of the Regulatory and QA departments for the company’s gene therapy candidates. Prior to that, Dr. Boman served as Chief Regulatory Officer at AveXis Inc. (now Novartis Gene Therapies) and has also held senior positions in regulatory affairs and clinical development at Alder BioPharmaceuticals, Cell Therapeutics, Genentech, and Amgen. 

Dr. Boman received her M.D. in Human Medicine, her Ph.D. in Biochemistry, and B.Sc. in General Science from The University of British Columbia.

Dr. Healey joined Adicet in October 2020 as Chief Technology Officer with nearly two decades of experience in cell therapy development and manufacturing. He joins Adicet most recently from KBI Biopharma Inc., a biopharmaceutical contract services organization, where he was responsible for establishing process development, manufacturing, quality control and facilities management for biopharmaceutical clients developing cellular therapies. Previously, he served as Chief Scientific Officer at Opexa Therapeutics, Inc., where he was responsible for all pre-clinical scientific development, closed-system process design and the scaling of Opexa's autologous T-cell immunotherapy. Dr. Healey has also served as Director of Immunology at Argos Therapeutics Inc. and Group leader for Immunology at ML Laboratories, UK, (formerly Cobra Biotherapeutics). Dr. Healey received his Ph.D. from University of London, and holds a B.Sc. in Cellular Pathology from Bristol University.

Mr. Harvey has served as Chief Financial Officer for Adicet since September 2020. He has more than 20 years of experience in building and financing life science and technology businesses. Most recently, he served as Chief Financial Officer of Centrexion Therapeutics, a privately held biotech. Previously, he served as the Chief Financial Officer of Radius Health for over ten years. At Radius, he helped the company successfully complete its initial public offering in 2014 and transition from research and development to commercialization. During his tenure at Radius, he oversaw financial operations, business development, legal, facilities, and information technology. Prior to that, he was Managing Director at Shiprock Capital, a venture capital firm, where he managed investments and development of early and expansion-stage companies. Mr. Harvey received his MBA from Harvard Business School, and earned both a law degree and an undergraduate degree in Economics from the Australian National University.

Amy Locke is Chief Human Resources Officer of Adicet Bio. As the Company advances its broad pipeline, Ms. Locke is leading Adicet’s talent acquisition, retention and development efforts.

With nearly 30 years’ experience in cross functional leadership and senior HR roles at both startup and mature life sciences companies, Ms. Locke specializes in building the HR function in rapidly evolving organizations with an eye toward organizational development, leadership team optimization, talent acquisition and retention, training and development, and culture-building.

She has served in various HR, commercial learning and organizational development roles at Bristol Myers Squibb, Genentech, Natera, ZS Pharma, InterMune and Allakos. 

Ms. Locke earned a Bachelor of Business Administration from the University of North Texas and has certifications in Organizational Development, Leadership Development and Human Capital Strategy.

Alice Bertaina, M.D., Ph.D.

SAB

Dr. Bertaina is an Associate Professor of Pediatrics - Stem Cell Transplantation in the department of Stem Cell Transplantation and Regenerative Medicine and a pediatric hematologist/oncologist at Lucile Packard Children’s Hospital at Stanford University. She is an expert in the field of allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients affected by hematological malignancies or nonmalignant disorders. Prior to joining Stanford, she was Head of the Stem Cell Transplant Unit in the Department of Hematology and Oncology at the Bambino Gesù Children’s Hospital in Rome. Dr. Bertaina obtained her M.D. degree at the University of Pavia, Italy; fellowship in HSCT at the Bambino Gesù Children’s Hospital, Rome, and Ph.D. degree in Immunology and Biotechnology at Tor Vergata University in Rome.

Marco Davila, M.D., Ph.D.

SAB

Dr. Davila’s research is dedicated to developing gene-engineered cell therapies that target cancer. The goal of this research is to identify optimal cell therapies or combination therapies involving cells that will improve responses in cancer patients. He has worked and developed cell therapies that are now FDA-approved for patients with B cell malignancies and has partnered with academic and industry partners to translate novel cell therapies for diseases such as AML, ovarian cancer, B cell malignancies, and lung cancer. Dr. Davila currently serves as the Senior Vice President for Translational Research at the Roswell Park Comprehensive Cancer Center, which puts him at the interface of rapidly translating novel cellular therapies to cancer patients. 

Constantine Mitsiades, M.D., Ph.D.

SAB

Dr. Mitsiades is Assistant Professor of Medicine at Harvard Medical School in the Department of Medical Oncology at Dana-Farber Cancer Institute, and his research focuses on understanding and overcoming the mechanisms of tumor cell resistance to pharmacological and immune-based therapies. He received his M.D., Ph.D., and a master’s degree in Basic and Clinical Medical Sciences from the University of Athens, School of Medicine, in Greece. He also received a master’s degree in Medical Sciences from Harvard Medical School.

Michael Kalos, Ph.D.

SAB

Dr. Michael Kalos is an internationally recognized expert in T cell therapy and immunotherapy and brings over 25 years of experience in the fields of cell therapy, oncology vaccines, and immune-oncology. Previously, Dr. Kalos was Executive Vice President and Head of Research and Development at ArsenalBio. He also served as Vice President, Immuno-oncology and Oncology Cell Therapies, at Janssen, the Pharmaceutical Companies of Johnson and Johnson, and chief scientific officer at Eli Lilly & Company. Dr. Kalos’s academic lab at UPenn played a key role in the early clinical development of Kymriah, including developing the methodologies and strategies to enable robust pharmacodynamic and mechanistic analysis of CAR T therapies. He obtained his Ph.D. from the University of Minnesota and completed post-doctoral training in the laboratory of Phil Greenberg at the Fred Hutchinson Cancer Research Center.

Saul Priceman, Ph.D.

SAB

Dr. Saul Priceman is an Associate Professor in the Department of Medicine at USC, and the Founding Director of the KSOM/Norris Center for Cancer Cellular Immunotherapy Research. Over the last 14 years, his research has focused on T cell immunobiology and cancer immunotherapies. Dr. Priceman’s laboratory develops CAR T cell therapies and combinatorial approaches for the treatment of solid cancers, bringing several therapies to phase 1 clinical testing. His research has led to high-impact publications in Nature Medicine, Science Translational Medicine, Nature Communications, and Cell Metabolism, with numerous patents and technologies licensed for further clinical development. Dr. Priceman’s research has been funded with grants from the NCI, DOD, CIRM, and Prostate Cancer Foundation. He received his B.S. in microbiology at UCSB, his Ph.D. in molecular and medical pharmacology at UCLA, and his postdoctoral research at City of Hope.